Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 7Non Small Cell Lung Cancer Metastatic 3Neoplasm Metastasis 3Recurrence 2Advanced Non-Small Cell Lung Cancer 2ALK Positive Non-small Cell Lung Cancer 2Sexual Dysfunction, Physiological 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neurofibromatosis 1 1Neoplasms 1Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Meningeal Carcinomatosis 1Lung Diseases 1Hyperlipidemias 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Erectile Dysfunction 1Colorectal Neoplasms 1Brain Neoplasms 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive × lorlatinib × Thoracic × Clear all
NCT03178071 2019-11-04

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Pfizer

No longer available
Thoracic

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡